Literature DB >> 8396372

Soluble and cellular markers of T cell activation in patients with pulmonary sarcoidosis.

B E Hol1, R Q Hintzen, R A Van Lier, C Alberts, T A Out, H M Jansen.   

Abstract

We have characterized the activation state of T cells in the bronchoalveolar lavage fluid (BALF) and peripheral blood (PB) from patients with sarcoidosis, to obtain more information about their mechanisms of activation. We analyzed the expression of activation markers (CD25, HLA-DR, Leu-8, and two recently defined markers, CD69 and CD27) on T cells by two-color flow cytometry. We also measured the levels of soluble CD27 and soluble CD25 in nonconcentrated BALF and in serum by ELISA. We found that most T cells in BALF from patients, but not in the peripheral blood, expressed CD69, whereas they did not express CD27. The phenotype (CD69+CD27-) of most BALF T cells and the coexpression of CD69 with HLA-DR and/or VLA-1 indicates that they are in a state of recent and persistent activation. We confirmed previous findings of expression of CD25, HLA-DR, and Leu-8 by T lymphocytes in BALF from patients. We also confirmed increased levels of soluble CD25 in the serum from these patients. The levels of sCD27 and sCD25 in the epithelial lining fluid (ELF) were calculated on the basis of urea in BALF and serum. They were increased in the patients compared with control subjects. In both patients and control subjects, levels in ELF were higher than in the peripheral blood. This indicates shedding of sCD27 (and sCD25) in the lung compartment, which likely contributes to levels in the serum. It is known that in vitro CD27+ cells become CD27- after repeated stimulation and that CD27- cells, after restimulation, do not shed sCD27.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396372     DOI: 10.1164/ajrccm/148.3.643

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  8 in total

1.  Phenotypic analysis of lymphocytes and monocytes/macrophages in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis.

Authors:  J Wahlström; M Berlin; C M Sköld; H Wigzell; A Eklund; J Grunewald
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

2.  Biological role of the soluble interleukin-2 receptor in sarcoidosis.

Authors:  Remi M M Vanmaris; Ger T Rijkers
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

3.  Differential expression of cytokine genes in CD27-positive and -negative CD4 lymphocyte subsets from healthy humans and rheumatoid arthritis patients.

Authors:  I Stonãns; E Stonãne; H Vogelsang; U Junker; L Jäger
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

4.  Therapeutic granulocyte and monocyte apheresis (GMA) for treatment refractory sarcoidosis: a pilot study of clinical effects and possible mechanisms of action.

Authors:  H H Olsen; V Muratov; K Cederlund; J Lundahl; A Eklund; J Grunewald
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

5.  Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course.

Authors:  A J Swaak; R Q Hintzen; V Huysen; H G van den Brink; J T Smeenk
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

6.  Interaction of disease-related antigen-reactive T-cell lines from multiple sclerosis patients with type IV collagen: role of integrin VLA-1 and effects of irradiation.

Authors:  Ilan Bank; Anat Achiron; Gad Levie; Alexander Koltakov; Mathilda Mandel
Journal:  J Clin Immunol       Date:  2002-05       Impact factor: 8.317

7.  Lung lymphocytes proliferate minimally in the murine pulmonary immune response to intratracheal sheep erythrocytes.

Authors:  G D Seitzman; J Sonstein; S Kim; W Choy; J L Curtis
Journal:  Am J Respir Cell Mol Biol       Date:  1998-06       Impact factor: 6.914

8.  Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung.

Authors:  Godelieve J de Bree; Ester M M van Leeuwen; Theo A Out; Henk M Jansen; René E Jonkers; René A W van Lier
Journal:  J Exp Med       Date:  2005-11-21       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.